Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
96M
-
Number of holders
-
271
-
Total 13F shares, excl. options
-
79.1M
-
Shares change
-
-1.18M
-
Total reported value, excl. options
-
$3.69B
-
Value change
-
-$57.7M
-
Put/Call ratio
-
0.41
-
Number of buys
-
146
-
Number of sells
-
-95
-
Price
-
$46.69
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2024
309 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q1 2024.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 271 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 79.1M shares
of 96M outstanding shares and own 82.46% of the company stock.
Largest 10 shareholders include VANGUARD GROUP INC (8.7M shares), RTW INVESTMENTS, LP (7.09M shares), BlackRock Inc. (5.24M shares), WELLINGTON MANAGEMENT GROUP LLP (4.1M shares), SANDS CAPITAL MANAGEMENT, LLC (3.86M shares), PRICE T ROWE ASSOCIATES INC /MD/ (3.57M shares), STATE STREET CORP (2.85M shares), Clearbridge Investments, LLC (2.4M shares), ALKEON CAPITAL MANAGEMENT LLC (2.24M shares), and FEDERATED HERMES, INC. (1.94M shares).
This table shows the top 271 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.